Molecular diagnostic co ImmunArray raises $10mJul. 14, 2016
Israeli molecular diagnostic company ImmunArray has closed a Series B financing round led by private investment firm Exigent. With offices in Rehovot and Richmond, Virginia, ImmunArray has developed novel blood tests and pioneers new and more accurate ways to diagnose autoimmune diseases such as lupus as well as traumatic brain injury (TBI).
The company was founded in 2006 based on iCHIP technology licensed from the Weizmann Institute of Science. iCHIP technology can determine the presence of a specific set of molecular biomarkers that are linked to particular disease or condition. The company’s first commercially available test is the SLE-Key Rule-Out Test, to definitively establish that a patient does not have Systemic Lupus Erythematosus (SLE) or lupus. ImmunArray also was a grant recipient of the GE-NFL Head Health Challenge and is developing a simple test with the accuracy, sensitivity and specificity to determine whether or not a person has received a concussion or other forms of traumatic brain injury. Other tests for more chronic follow up in brain injury also are under development.